iSpecimen (NASDAQ:ISPC) operates an on-demand biospecimen marketplace that connects life science researchers with accredited biorepositories, hospitals and private biobanks. By leveraging its digital platform, the company streamlines procurement of human biospecimens—such as blood, tissue and body fluids—accompanied by detailed clinical, demographic and pathology data. Researchers in pharmaceutical, diagnostic and academic settings use iSpecimen’s network to accelerate study timelines and reduce the administrative burden of specimen sourcing.
The company offers end-to-end services, including specimen identification, quality control, donor consent verification and comprehensive data annotation. iSpecimen’s proprietary software manages logistics, tracking and regulatory compliance across multiple jurisdictions. Additionally, the firm provides customizable solutions for longitudinal sampling studies, clinical trial support and biomarker discovery initiatives, enabling clients to access rare or disease-specific materials with greater precision.
iSpecimen serves a global customer base spanning North America, Europe and parts of Asia, partnering with over 600 hospitals and research institutions. By maintaining relationships with institutional review boards and ethics committees, the company ensures that all specimens adhere to applicable patient privacy and consent standards. Its scalable supply chain infrastructure facilitates both small-scale feasibility studies and large-cohort research projects.
Founded in 2014 and headquartered in the Boston area, iSpecimen is led by Chief Executive Officer Ron Erickson and a management team with deep experience in life sciences, diagnostics and healthcare technology. The company’s mission centers on democratizing access to high-quality human samples, reducing the time and cost barriers that often hamper translational research and drug development efforts.
